We propose initiating early phase (Phase I/II) trials focusing on inflammation- and metabolism-associated solid tumours, such as CRC and PDAC, where GLP-1 RAs may exert the greatest benefit. This evidence concerns the gene GLP1R and colorectal carcinoma.